Results 211 to 220 of about 3,108,169 (356)

Risk Factors and Comparative Safety of Anti-PD-1 Combination Therapies in Advanced Melanoma: A Nationwide Real-World Cohort Study From China. [PDF]

Cancer Med
Qiao Y, Fu X, Shukar S, Ge W, Yang W, Jiang RB, Dai X, Chen H, Zhao J, Tang M, Mu F, Wang H, Wu Q, Xia X, Zhang Y, Ji S, Xu Y, Cao R, Wang J, Yao Y, Wang J, Fang Y.   +21 more
europepmc   +1 more source

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment

Advanced Science, EarlyView.
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs, Pranay Nath, Alice Chen, Rizwan Romee, Andreia Maia   +4 more
wiley   +1 more source

Clinical Effectiveness and Safety of Electrochemotherapy (ECT) in the Treatment of Locally Advanced Melanoma: A Systematic Review. [PDF]

Cureus
Vickars DJ, Mandal A.
europepmc   +1 more source

Caveolin‐1 Stabilizes SERCA2 to Counteract Acute Kidney Injury via Suppression of Ca2+‐Dependent Endoplasmic Reticulum Stress in Distal Tubules

Advanced Science, EarlyView.
In AKI, initial kidney injury upregulates the expression of Cav‐1, which subsequently binds to and stabilizes SERCA2 via its scaffolding domain and through deubiquitination, thereby regulating Ca2+ homeostasis and ER stress. Conversely, Cav‐1 deficiency accelerates SERCA2 degradation, triggering Ca2+ overload and ER stress, and ultimately exacerbating ...
Yan Zhang, Xin He, Hao Huang, Rong Lu, Xin Lv, Shenglan Li, Sijue Zou, Jiawei Cheng, Yiwei Xiong, Zhenghao Deng, Qiongjing Yuan, Yanyun Xie, Ling Huang, Jiaxi Pu, Shao Liu, Qianbin Li, Jie Meng, Huixiang Yang, Lijian Tao, Zhangzhe Peng   +19 more
wiley   +1 more source

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

Hepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode, Takahiro Kodama, Satoshi Shigeno, Kazuhiro Murai, Satoshi Tanaka, Justin Y. Newberg, Jumpei Kondo, Shogo Kobayashi, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Hiroshi Suemizu, Tomohide Tatsumi, Hidetoshi Eguchi, Nancy A. Jenkins, Neal G. Copeland, Tetsuo Takehara   +16 more
wiley   +1 more source

Circulating cellular communication network factor 1 (CCN1) as a liquid biopsy marker indicating progression in advanced melanoma. [PDF]

J Transl Med
Heidrich I, Reese KL, Ullemeyer H, Kött J, Freiberg H, Geidel G, Rünger A, Hansen-Abeck I, Abeck F, Schneider SW, Gebhardt C, Pantel K, Smit DJ.   +12 more
europepmc   +1 more source

Mechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy

Advanced Science, EarlyView.
MISPOP integrates ensemble learning with membrane‐active physicochemical priors to identify Dermaseptin‐S9, a natural oncolytic peptide that disrupts tumor membranes, triggers immunogenic cell death, and shows strong antitumor activity. The study illustrates a mechanism‐informed route from peptide sequence data to cancer immunotherapy leads.
Wen Zhang, Shengxin Lu, Guangyong Zheng, Shensuo Li, Hongyu Chen, Mei Hong, Xiangru Zhou, Ruotian Tang, Ye Wu, Weidong Zhang, Dong Lu, Xin Luan   +11 more
wiley   +1 more source

Harnessing the synergy of contact brachytherapy and immune checkpoint inhibitors in advanced melanoma: first reported case series. [PDF]

Rep Pract Oncol Radiother
Chyrek AJ, Galus Ł, Mackiewicz J, Kluska A, Burchardt WM, Chicheł A.   +5 more
europepmc   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

Annals of Gastroenterological Surgery, EarlyView.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu, Yoshiyuki Tagayasu, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Yukio Fujiwara, Kazuto Harada, Keisuke Kosumi, Yoshifumi Baba, Masaaki Iwatsuki   +9 more
wiley   +1 more source

Protein content of extracellular vesicles from patients with advanced melanoma changes upon progression to anti-PD1 therapy. [PDF]

Sci Rep
Trilla-Fuertes L, Gámez-Pozo A, Laso-García F, Maqueda G, Becerril-Gómez F, Sánchez L, Díaz-Almirón M, Lalanda-Delgado P, García-Carneros A, López-Vacas R, Beato M, Roschitzki B, Gutiérrez-Fernández M, Nanni P, Vara JÁF, Espinosa E.   +15 more
europepmc   +1 more source